These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23121368)

  • 1. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection.
    Coppola N; Stanzione M; Messina V; Pisaturo M; De Pascalis S; Macera M; Tonziello G; Fiore M; Sagnelli C; Pasquale G; Sagnelli E
    J Viral Hepat; 2012 Dec; 19(12):890-6. PubMed ID: 23121368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.
    Martín-Carbonero L; Teixeira T; Poveda E; Plaza Z; Vispo E; González-Lahoz J; Soriano V
    AIDS; 2011 Jan; 25(1):73-9. PubMed ID: 21076274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B.
    Moutinho RS; Perez RM; Medina-Pestana JO; Figueiredo MS; Koide S; Alberto FL; Silva AE; Ferraz ML
    J Med Virol; 2006 Oct; 78(10):1284-8. PubMed ID: 16927290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
    Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
    Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B].
    Altindiş M; Uslan I; Cetinkaya Z; Yüksel S; Ciftçi IH; Demirtürk N; Ozdemir M; Arslan F; Aktepe OC
    Mikrobiyol Bul; 2007 Apr; 41(2):227-33. PubMed ID: 17682709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.
    Saravanan S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
    J Microbiol Immunol Infect; 2009 Apr; 42(2):122-8. PubMed ID: 19597643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection.
    Bozdayi G; Türkyilmaz AR; Idilman R; Karatayli E; Rota S; Yurdaydin C; Bozdayi AM
    J Med Virol; 2005 Aug; 76(4):476-81. PubMed ID: 15977237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
    Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients.
    Filippini P; Coppola N; Pisapia R; Martini S; Marrocco C; Di Martino F; Sagnelli C; Filippini A; Sagnelli E
    J Med Virol; 2007 Nov; 79(11):1679-85. PubMed ID: 17854026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.